Remove 2003 Remove Marketing Remove Regulations
article thumbnail

NANOBIOTIX Announces Pricing of Global Offering and Approval to List on NASDAQ Global Select Market

The Pharma Data

The ADSs have been approved for listing on the Nasdaq Global Select Market and are expected to begin trading on December 11, 2020 under the ticker symbol “NBTX.” The Company’s ordinary shares are listed on the regulated market of Euronext Paris under the ticker symbol “NANO.”.

article thumbnail

Zigs & Zags – The Opposite of a Great Idea Can Also be a Great Idea

Perficient: Drug Development

Several books have been written on the concept, and many more refer to it when discussing differentiation and disruption within marketing and product development. It’s common that people view novel and innovative, first-to-market groups as having great ideas. The analogy of the “red ocean” of a saturated market drives home his point.

Marketing 116
article thumbnail

The Gig Economy, Nightwork, and Stimulant Use

Common Sense for Drug Policy Blog

Part of this 'performance' has to do with adapting to the different temporal demands of the labor market—in other words, the management of sleep and wakefulness. Melatonin, the hormone involved in the regulation of our biological clock, is released when we are exposed to daylight. As Crary ( 2013 , p.

article thumbnail

Article FDA Thank You FDA updates set the stage for broader use of harmonized standards for safety reporting

Agency IQ

FDA updates set the stage for broader use of harmonized standards for safety reporting Though long considered a top priority by regulators, the process to standardize and harmonize the submission of individual case safety reports (ICSRs) has been slow. Periodic Benefit-Risk Evaluation Reports ).

FDA 40
article thumbnail

Biophytis Announces Plan to Publicly File Later Today Registration Statement for Proposed Initial Public Offering in the United States

The Pharma Data

The company’s common shares are listed on the Euronext Growth Paris market (Ticker: ALBPS -ISIN: FR0012816825). The company is based in Paris, France, and Cambridge, Massachusetts. Disclaimer This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts.

article thumbnail

Article EMA Thank You The devil is in the details: a deep dive into the state of Notified Body designations

Agency IQ

The devil is in the details: a deep dive into the state of Notified Body designations While the European Commission has been laser-focused on the number of medical device and IVD certificates, AgencyIQ is taking a look at progress toward designating Notified Bodies to the European medical device and diagnostics regulations.

article thumbnail

To List or Not to List; That is the Question – The FTC Signals the Potential for Greater Scrutiny of Patent Information Submissions to FDA

FDA Law Blog: Biosimilars

It merely says that “[t]he Hatch-Waxman Act and FDA regulations set forth the criteria for listing patents in the Orange Book” and that “Brand manufacturers are responsible for ensuring their patents are properly listed.” But it is not always clear which types of patents are eligible for listing in the Orange Book.

FDA 104